Changing – Page 2

Kathy High Takes Helm at GV, ARCH-Backed Eye Disease Biotech RhyGaze; Arvinas Sees Leadership Shift

3 months ago talkbio0Tagged Arch of foot, Arvinas, Changing, Granulovirus, GV, Kathy, Leadership, RhyGaze

Kathy High, RhyGaze, GV, ARCH, eye disease biotech, Arvinas, leadership changes

RyCarma Therapeutics Unveils New Leadership and Company Name, Expands Focus on Heart Failure Treatment

3 months ago talkbio0Tagged ARMGO, biotech company, Cardiovascular Diseases, Changing, Heart failure, Leadership, Pharma, Rycals, RyCarma, skeletal muscle diseases

RyCarma Therapeutics, ARMGO Pharma, ryanodine receptor, Rycals, heart failure, cardiovascular diseases, skeletal muscle diseases, biotech company, new leadership, company name change.

Applied Therapeutics Undergoes Leadership Changes Amid FDA Rejection and Regulatory Challenges

4 months ago talkbio0Tagged Changing, disease drug, Govorestat, Leadership, regulatory, Rejection, United States Food and Drug Administration

Applied Therapeutics, leadership changes, FDA rejection, rare disease drug, govorestat, regulatory challenges

Biotech Industry Prepares for Trump 2.0: Regulatory Changes and M&A Activity Expected

4 months ago talkbio0Tagged biotech industry, Changing, Drug Industry, Health Policy, M&A activity, regulatory environment, Transplant Registry Unified Management Program, United States Food and Drug Administration

Biotech industry, Trump 2.0, FDA changes, M&A activity, regulatory environment, pharmaceutical industry, healthcare policy

Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals

5 months ago talkbio0Tagged Biopharma Industry, Changing, FTC, Health Policy, M&A, Policy, Regulation, second, Trump 's, United States Federal Trade Commission, Vaccines

Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty

Pfizer Appoints Chris Boshoff as New Chief Scientific Officer and President of Research & Development

5 months ago talkbio0Tagged Boshoff, Changing, Chris, Leadership, Mikael, Neoplasms, Pfizer, President brand of dental material, R&D, Research and Development, Scientific Officer

Pfizer, Chris Boshoff, Chief Scientific Officer, President of Research & Development, Mikael Dolsten, Leadership Changes, Oncology, R&D

BeiGene Rebrands as BeOne Medicines, Emphasizing Global Unity Against Cancer

5 months ago talkbio0Tagged BeiGene, Changing, Global Oncology, Malignant Neoplasms, Strategic Growth

BeiGene, BeOne Medicines, Global Oncology, Cancer Treatment, Name Change, Strategic Growth

Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients

6 months ago talkbio0Tagged Alzheimer 's disease, ARIA-E, Cerebral Edema, Changing, dosing, Eli, Eli Lilly, Kisunla, Risk, Treatment Protocols

Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction

Modified Dosing Regimen of Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Reduces Brain Swelling

6 months ago talkbio0Tagged Alzheimer 's disease, amyloid-related imaging abnormalities, ARIA-E, Cerebral Edema, Changing, Donanemab, dosing, Eli, Eli Lilly, Kisunla, oedema/effusion, TRAILBLAZER-ALZ, Treatment Protocols, Trial Phase 3B

Alzheimer’s disease, Eli Lilly, Kisunla (donanemab), Modified dosing regimen, ARIA-E (amyloid-related imaging abnormalities with oedema/effusion), Brain swelling, TRAILBLAZER-ALZ 6 Phase IIIb trial

Turnstone Biologics Undergoes Strategic Restructuring with Layoffs and Leadership Changes

6 months ago talkbio0Tagged Arenaria, Biological Factors, Changing, Industry, Leadership, restructuring, strategic

Turnstone Biologics, layoffs, leadership changes, strategic restructuring, biotech industry